[go: up one dir, main page]

ME02461B - Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih - Google Patents

Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih

Info

Publication number
ME02461B
ME02461B MEP-2016-96A MEP9616A ME02461B ME 02461 B ME02461 B ME 02461B ME P9616 A MEP9616 A ME P9616A ME 02461 B ME02461 B ME 02461B
Authority
ME
Montenegro
Prior art keywords
amino
methyl
fluorophenyl
oxadiazol
bromo
Prior art date
Application number
MEP-2016-96A
Other languages
English (en)
Inventor
Andrew P Combs
Eddy W Yue
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02461(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of ME02461B publication Critical patent/ME02461B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (14)

1. Jedinjenje formuleili njegova farmaceutski prihvatljiva so, za upotrebu u tretmanu kancera u kombinaciji sa anti-PD-1 antitelom gde su: W, X1, i X2 nezavisno izabrani od (CRaRb)t, (CRaRb)uO(CRaRb)v, (CRaRb)uC(O)(CRaRb)v, (CRaRb)uC(O)NRc(CRaRb)v, (CRaRb)uC(O)O(CRaRb)v, (CRaRb)uC(S)(CRaRb)u, (CRaRb)uC(S)NRc(CRaRb)v, (CRaRb)uS(O)(CRaRb)v, (CRaRb)uS(O)NRc(CRaRb)v, (CRaRb)uS(O)2(CRaRb)v, (CRaRb)uS(O)2NRc(CRaRb)v, (CRaRb)uNRc(CRaRb)v i (CRaRb)uC(=NRd)NRc(CRaRb)v;R2 je H, C1-6 alkil ili C3-7 cikloalkil;R3a i R5a su nezavisno izabrani od C1-8 alkila, C2-8 alkenila, C2-8 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila, svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy1, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;R3b je aril ili heteroaril svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;R5b je H, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil gde su spomenuti C1-8 alkil, C2-8 alkenil, C2-5 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil opciono supstituisani sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenilaC2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRh1R, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;Cy1 i Cy2 su opciono izabrani od arila, heteroarila, cikloalkila i heterocikloalkila, svaki supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, CN, NO2, ORe3, SRe3, C(O)Rf3, C(O)NRg3Rh3, C(O)ORe3, OC(O)Rf3, OC(O)NRg3Rh3, NRg3Rh3, NRg3C(O)Rh3, NRg3C(O)ORe3, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf3)2, P(ORe3)2, P(O)Re3Rf3, P(O)ORe3ORf3, S(O)Rf3, S(O)NRg3Rh3, S(O)2Rf3 i S(O)2NRg3Rh3;Ra i Rb su nezavisno izabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila, heterocikloalkilalkila, CN, NO2, ORe4, SRe4, C(O)Rf4, C(O)NRg4Rh4, C(O)ORe4, OC(O)Rf4, OC(O)NRg4Rh4, NRg4Rh4, NRg4C(O)Rh4, NRg4C(O)ORe4, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf4)2, P(ORe4)2, P(O)Re4Rf4, P(O)ORe4ORf4, S(O)Rf4, S(O)NRg4Rh4, S(O)2Rf4 i S(O)2NRg4Rh4;Rc je H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila ili cikloalkilalkila;Rd je H, ORd1, CN ili NO2;Rd1 je H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, arilalkil ili cikloalkilalkil;Rel, Re3 i R64 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilalkila;Rf1, Rf3 i Rf4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila;Rg1, Rg3 i Rg4 nezavisno su izabrani od H, C1-6 alkil, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;Rh1, Rh3 i Rh4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;ili Rg1 i Rh1 zajedno sa N atomom za koji su vezani formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu;ili Rg3 i Rh3 zajedno sa N atomom za koji su vezani formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu;ili Rg4 i Rh4 zajedno sa N atomom za koji su vezani formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu;Ri je H, CN ili NO2;a je 0 ili 1;b je 0 ili 1;n je 0 ili 1;p je 0 ili 1;t je 1, 2, 3, 4, 5 ili 6;u je 0, 1, 2, 3, 4, 5 ili 6; iv je 0, 1, 2, 3, 4, 5 ili 6.
2. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu R2 jeste H.
3. Jedinjenje ili so za upotrebu prema zahtevu 2, pri čemu n jeste 0.
4. Jedinjenje ili so za upotrebu prema zahtevu 3, pri čemu p jeste 1.
5. Jedinjenje ili so za upotrebu prema zahtevu 4, pri čemu R5b jeste H.
6. Jedinjenje ili so za upotrebu prema zahtevu 5, pri čemu a jeste 0.
7. Jedinjenje ili so za upotrebu prema zahtevu 6, pri čemu b jeste 0.
8. Jedinjenje ili so za upotrebu prema zahtevu 7, pri čemu R3b jeste fenil opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C1-6 alkinila, C1-4 haloalkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, P(Rf1)2, P(ORe1)2, P(O)Re1Rt1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)1Rf1 i S(O)2NRg1Rh1.
9. Jedinjenja ili so za upotrebu prema zahtevu 6, pri čemu b jeste 1.
10. Jedinjenja ili so za upotrebu prema zahtevu 9, pri čemu W jeste (CRaRb)t ili (CRaRb)uO(CRaRb)v.
11. Jedinjenje ili so za upotrebu prema zahtevu 10, pri čemu R3b je heteroaril, opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, Ng1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1 P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1.
12. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu jedinjenje ima formulu: gde je: X1 (CRaRb)t ili (CRaRb)uC(O)(CRaRb)v; R3a je C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil, svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy1, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1Rf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1; R3b je aril ili heteroaril, svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1; R5b je H, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil; gde su spomenuti C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1R , NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe10Rf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1; Cy1 i Cy2 su nezavisno izabrani kao aril, heteroaril, cikloalkil i heterocikloalkil, svaki opciono supstituisan sa 1, 2, 3,4 ili 5 supstituenata nezavisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, CN, NO2, ORe3, SRe3, C(O)Rf3, C(O)NRg3Rh3, C(O)ORe3, OC(O)Rf3, OC(O)NRg3Rh3, NRg3Rh3, NRg3C(O)Rh3, NRg3C(O)ORe3, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf3)2, P(ORe3)2, P(O)Re3Rf3, P(O)ORe3ORf3, S(O)Rf3, S(O)NRg3Rh3, S(O)zRf3 i S(O)2NRg3Rh3; Ra i Rb su nezavisno izabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila, heterocikloalkilalkila, CN, NO2, ORe4, SRe4, C(O)Rf4, C(O)NRg4Rh4, C(O)ORe4, OC(O)Rf4, OC(O)NRg4Rh4, NRg4Rh4, NRg4C(O)Rh4, NRg4C(O)ORe4, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf4)2, P(ORe4)2 P(O)Re4Rf4, P(O)ORe4ORf4, S(O)Rf4, S(O)NRg4Rh4, S(O)2Rf4 i S(O)2NRg4Rh4; Re1, Re3 i Re4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilalkila; Rf1, Rf3 i Rf4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila; Rg1, Rg3 i Rg4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila; Rh1, Rh3 i Rh4 su nezavisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila; ili Rg1 i Rh1 zajedno sa N atomom za koji su vezani, formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; ili Rg3 i Rh3 zajedno sa N atomom za koji su vezani, formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; ili Rg4 i Rh4 zajedno sa N atomom za koji su vezani, formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; Ri je H, CN ili NO2; a je 0 ili 1; t je 1, 2, 3, 4, 5 ili 6; u je 0, 1, 2, 3, 4, 5 ili 6; i v je 0, 1, 2, 3, 4, 5 ili 6.
13. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu je jedinjenje izabrano od: N-benzil-4-(benzilamino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; 4-[(anilinokarbonil)amino]-N-(3-hlorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; Terc-butil{4-[({4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]benzil} karbamat; 4-(aminometil)-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; 4-{[(benzilamino)karbonil]amino}-N-(3-bromo-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}morfolin-4-karboksamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-(metilamino)-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-4-karboksamid; Terc-butil4-{4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino) karbonil]benzil}piperazin-1-karboksilat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(piperazin-1-ilmetil) benzamid; 1-benzoil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin- 4-karboksamid; N(4)-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-N(1)-fenilpiperidin- 1,4-dikarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-etilpiperidin-4- karboksamid; 4-[(benzoilamino)metil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol- 3-il}benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-cijanofenoksi) acetamid; N-{4-[(E,Z-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilpiperidin-4-karboksamid; N-(3-bromo-4-fluorofenil)-4-({4-[(1,1-dioksidotiomorfolin-4-il)metil]benzil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-{[4-(morfolin-4-ilmetil)benzil]amino}-1,2,5-oksadiazol-3-karboksimidamid; N-(3-cijano-4-fluorofenil)-4-({4-[(1,1-dioksidotiomorfolin-4-il)metil]benzil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(piridin-3-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; N-(3-cijano-4-fluorofenil)-N’-hidroksi-4-[(piridin-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; 4-[(3-cijanobenzil)amino]-N-(3-cijano-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(1H-tetrazol-5-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklopentankarboksamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il} izonikotinamid; N-{4-[(E,Z-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksibenzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metoksibenzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metoksibenzamid; 2-hloro-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; 3-hloro-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; 4-hloro-N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-jodobenzamid; N-{4-[(E,Z)-[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-cijanobenzamid; N-{4-[(E,Z)-{[4-fluoro-3-(trifluorometil)fenil]amino}(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z-{[4-fluoro-3-(trifluorometil)fenil]amino}(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}izonikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il} izonikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-cijanobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-cijanobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-naftamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-naftamid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-furamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}tiofen-2-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-fenil-5-(trifluorometil)- 1H-pirazol-4-karboksamid; 4-(acetilamino)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid Terc-butil {4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil] benzil}karbamat N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-benzotiofen-2-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-benzotiofen-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}tiofen-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1H-imidazol-2-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-1,2,3-tiadiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,2,3-tiadiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,1-benzizoksazol-3-karboksamid; 4-(aminometil)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-({[(2-feniletil)amino]karbonil}amino)-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-{[(ciklopentilamino)karbonil]amino}-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-({[(3-cijanofenil)amino]karbonil}amino)-N’-hidroksi-1,2,5-oksadiazol-3 -karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-terc-butil-1-metil-1H-pirazol-5 -karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksiacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklopentankarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}butanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}cikloheksankarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1H-benzimidazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenoksiacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklobutankarboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-piridin-3-ilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}kinolin-6-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-hlorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-bromofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-fluorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-terc-butilfenoksi) acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-hlorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3,4-dihlorofenoksi) acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-naftiloksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2,3-dihlorofenoksi) acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-hlorofenoksi)-2-metilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-hlorofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-metoksifenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-metoksifenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-metoksifenoksi)acetamid; Benzil {4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}karbamat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-1-karboksamid; N-(3-bromo-4-fluorofenil)-4-({[(3-cijanofenil)(metil)amino]karbonil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; 4-({[benzil(metil)amino]karbonil}amino)-N-(3-bromo-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenilacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-metoksifenil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-metoksifenil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-metoksifenil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-cijanobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-bromofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-bromofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-hlorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-hlorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-fluorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-fluorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-hlorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-metilfenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-(trifluorometil)fenil) propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-fluorofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-metoksifenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-metoksifenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-metoksifenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-metilfenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-[4-(trifluorometil)fenil] propanamid; 3-[2,5-bis(trifluorometil)fenil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamid; 3-[3,5-bis(trifluorometil)fenil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metil-3-fenilpropanamid; 2-benzil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-[4-(trifluorometil) pirimidin-2-il]piperidin-4-karboksamid; 1-benzil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-terc-butil-1H-pirazol-5-karboksamid; 2-(benziloksi)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(4-hlorofenil)ciklopentan karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-fenoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,4,6-trihlorobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,2-difenilacetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(trifluorometoksi)benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,4-dimetoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-nitrofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}bifenil-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2,6-dihlorobenzil)-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,6-dimetoksibenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-nitrobenzamid; 5-bromo-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-tienil)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilbutanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,2-dimetilpropanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(morfolin-4-ilmetil)benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-[(1,1-dioksidotiomorfolin- 4-il)metil]benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(fenilacetil)piperidin-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(metilsulfonil)piperidin-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-piridin-4-il-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-nitrobenzamid; N-(4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-nitrobenzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-izopropilpiperidin-4-karboks amid; Terc-butil 4-{4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]-1,3-tiazol-2-il}piperidin-1-karboksilat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenil-1,3-tiazol-4-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metil-1,3-tiazol-4-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-piperidin-4-il-1,3-tiazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-cijanofenoksi)acetamid; Terc-butil 3-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil] piperidin-1-karboksilat; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-nitrofenil)propanamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-nitrofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-nitrofenoksi)acetamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-piridin-3-il-1,3-tiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-1,3-tiazol-5-karboks amid; 2-amino-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-tiazol-4-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-pirazin-2-il-1,3-tiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-[4-(trifluorometil) fenil]-1,3-tiazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,4-dimetil-1,3-tiazol-5-karboksamid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}pirolidin-2-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,5-dimetil-1H-pirazol-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-5-hloro-1-metil-1H-pirazol-4-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-dimetil-1H-pirazol-5-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-metil-1H-imidazol-2-karboksamid; 4-[(acetilamino)metil]-N-{4-[(E,Z-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3- il}benzamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metilpiperidin-4-karboks amid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-3-karboks amid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metilpiperidin- 4-karboksamid; 1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilpiperidin- 4-karboksamid; 4-(benzilamino)-N-(3-bromo-4-fluorofenil)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-etilpiperidin-3-karboksamid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-etilpiperazin-1-karboksamid; 4-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperazin-1-karboks amid; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(1-etilpiperidin- 4-il)-1,3-tiazol-4-karboksamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(1,3-tiazol-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-[(4-cijanobenzil)amino]-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-{[(1-metilpiperidin-4-il)metil]amino}-1,2,5-oksadiazol-3 -karboksimidamid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-{[4-(piperazin-1-ilmetil)benzil]amino}-1,2,5-oksadiazol-3-karboksimidamid; N-(3-bromo-4-fluorofenil)-4-({4-[(4-etilpiperazin-1-il)metil]benzil}amino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimid amid; N-(3-bromo-4-fluorofenil)-N’-hidroksi-4-[(piridin-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamid; i N-(3-bromo-4-fluorofenil)-4-[(3-cijanobenzil)amino]-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid; N-{4-[[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenilacetamid; N-{4-[[(3-hlorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; i N-{4-[(benzilamino)(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid; ili njihove farmaceutski prihvatljive soli.
14. Jedinjenje ili so za upotrebu prema zahtevu 1, pri čemu je spomenuti kancer izabran od kancera debelog creva, pankreasa, kancera dojke, kancera prostate, kancera pluća, kancera mozga, kancera jajnika, cervikalnog kancera, kancera testisa, kancera bubrega, kancera glave i vrata, limfoma, leukemije i melanoma.
MEP-2016-96A 2005-05-10 2006-05-09 Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih ME02461B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67950705P 2005-05-10 2005-05-10
EP12178315.3A EP2559690B1 (en) 2005-05-10 2006-05-09 Modulators of indoleamine 2,3-dioxygenase and methods of using the same

Publications (1)

Publication Number Publication Date
ME02461B true ME02461B (me) 2017-02-20

Family

ID=37396891

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-96A ME02461B (me) 2005-05-10 2006-05-09 Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih

Country Status (33)

Country Link
US (6) US8034953B2 (me)
EP (3) EP3085697A1 (me)
JP (2) JP4990270B2 (me)
KR (2) KR101386494B1 (me)
CN (2) CN101212967A (me)
AR (1) AR054271A1 (me)
AU (1) AU2006244068B9 (me)
BR (2) BR122020016659B8 (me)
CA (1) CA2606783C (me)
CR (1) CR9485A (me)
CY (2) CY1113989T1 (me)
DK (2) DK1879573T3 (me)
EA (1) EA026785B1 (me)
ES (2) ES2578404T3 (me)
GE (1) GEP20217221B (me)
HK (2) HK1117392A1 (me)
HR (2) HRP20130220T1 (me)
HU (1) HUE029214T2 (me)
IL (2) IL186957A (me)
ME (1) ME02461B (me)
MX (1) MX2007013977A (me)
MY (1) MY153424A (me)
NO (2) NO340487B1 (me)
NZ (1) NZ562919A (me)
PL (2) PL1879573T3 (me)
PT (2) PT2559690T (me)
RS (2) RS54876B1 (me)
SG (3) SG10201809390QA (me)
SI (2) SI2559690T1 (me)
TW (1) TWI377060B (me)
UA (1) UA99897C2 (me)
WO (1) WO2006122150A1 (me)
ZA (1) ZA200709698B (me)

Families Citing this family (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062438A1 (en) * 2002-01-22 2003-07-31 Biomatera Inc. Method of drying biodegradable polymers
WO2006082030A1 (en) * 2005-02-04 2006-08-10 Ctg Pharma S.R.L. New 4-aminoquinoline derivatives as antimalarials
MX2007009811A (es) 2005-02-14 2007-09-07 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il 17f, y sus usos.
ME02461B (me) 2005-05-10 2017-02-20 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
DE102005053947A1 (de) * 2005-11-11 2007-05-16 Univ Ernst Moritz Arndt Neue Arzneimittel
WO2007075598A2 (en) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007095050A2 (en) * 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
BRPI0719122A2 (pt) * 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP2064207B1 (en) * 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036652A2 (en) * 2006-09-19 2008-03-27 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
KR20090053923A (ko) 2006-09-22 2009-05-28 노파르티스 아게 헤테로시클릭 유기 화합물
US20080182882A1 (en) * 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
BRPI0720452A2 (pt) 2006-12-20 2014-01-14 Novartis Ag Compostos orgânicos
WO2008115804A1 (en) * 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
US20090170842A1 (en) 2007-11-14 2009-07-02 University Of Kansas Brca1-based breast or ovarian cancer prevention agents and methods of use
EP2227233B1 (en) * 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
WO2009124252A2 (en) * 2008-04-03 2009-10-08 Lankenau Institute For Medical Research Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases
PT3320912T (pt) 2008-04-17 2021-05-24 Io Biotech Aps Imunoterapia à base de indoleamina 2,3-dioxigenase
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
PL2480539T3 (pl) * 2009-09-25 2013-11-29 Bayer Cropscience Ag N-(1,2,5-oksadiazol-3-ilo)benzamidy i ich zastosowanie jako herbicydy
JP2012041325A (ja) * 2010-08-23 2012-03-01 Bayer Cropscience Ag オキサジアゾリノン誘導体およびその有害生物の防除用途
JP6063392B2 (ja) * 2010-12-22 2017-01-18 イドゲン アクチエボラグＩｄｏｇｅｎ ＡＢ 自己免疫性障害または臓器免疫拒絶による苦痛を治療するための、インドールアミン−２，３−ジオキシゲナーゼ（ｉｄｏ）を誘導する少なくとも２つの化合物を含んでなる組成物
NO2694640T3 (me) 2011-04-15 2018-03-17
AR088886A1 (es) 2011-11-16 2014-07-16 Basf Se Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
EP2780340A1 (en) * 2011-11-18 2014-09-24 Basf Se Substituted 1,2,5-oxadiazole compounds and their use as herbicides iii
KR101229365B1 (ko) * 2012-07-02 2013-02-18 대한민국 〔ｚ〕­ｎ­〔３­〔２，４­디플루오로페닐아미노〕­１­〔４­나이트로페닐〕­３­옥소프로프­１­엔­２­일〕­２­메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CN105377812B (zh) 2013-06-21 2018-09-18 组合化学工业株式会社 2-氨基-2-肟基-n-烷氧基亚氨代乙酰基氰化物的制备方法及其制备中间体
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
RU2536041C1 (ru) * 2013-10-11 2014-12-20 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) 3,3'-бис(фтординитрометил-onn-азокси)-4,4'-дифуразаниловый эфир и способ его получения
EP3744715A1 (en) * 2013-11-08 2020-12-02 Incyte Holdings Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
KR102457145B1 (ko) 2013-12-24 2022-10-19 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 트리시클릭 화합물
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP2017525753A (ja) * 2014-06-06 2017-09-07 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
CN106794176A (zh) * 2014-08-13 2017-05-31 奥克兰联合服务有限公司 色氨酸双加氧酶(ido1和tdo)的抑制剂和其在治疗中的用途
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
US10183082B2 (en) * 2014-09-09 2019-01-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. PET probes of radiofluorinated carboximidamides for IDO-targeted imaging
CN105481789B (zh) * 2014-09-15 2020-05-19 中国科学院上海有机化学研究所 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
JP2017538678A (ja) 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
WO2016106302A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CA2973602A1 (en) 2015-03-02 2016-09-09 Rigel Pharmaceuticals, Inc. Tgf-.beta. inhibitors
JP2018516238A (ja) 2015-04-03 2018-06-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
RU2717577C2 (ru) 2015-04-21 2020-03-24 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное имидазоизоиндола, способ его получения и медицинское применение
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
JP6797137B2 (ja) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CA2990335A1 (en) * 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
KR20180025897A (ko) 2015-07-14 2018-03-09 교와 핫꼬 기린 가부시키가이샤 항체와 조합 투여되는 ido 억제제를 포함하는 종양 치료제
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EA201792256A1 (ru) 2015-07-24 2018-07-31 Ньюлинк Дженетикс Корпорейшн Соли и пролекарства 1-метил-d-триптофана
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2017035118A1 (en) 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN106565696B (zh) * 2015-10-09 2020-07-28 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
BR112018008867A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e seus usos
CN108472245A (zh) 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
WO2017091577A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP3366691A1 (en) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3389783B1 (en) 2015-12-15 2024-07-03 Merck Sharp & Dohme LLC Novel compounds as indoleamine 2,3-dioxygenase inhibitors
CN106883193B (zh) * 2015-12-15 2021-10-15 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
KR102738306B1 (ko) 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
CN106883194A (zh) * 2015-12-16 2017-06-23 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
US9624185B1 (en) * 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
SG11201806480UA (en) 2016-02-02 2018-08-30 Emcure Pharmaceuticals Ltd Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN107033097B (zh) * 2016-02-04 2022-02-08 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
JP7066186B2 (ja) * 2016-02-19 2022-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肥満の処置のための方法及び医薬組成物
CN108884104B (zh) * 2016-02-19 2021-01-15 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
KR20220033522A (ko) 2016-03-04 2022-03-16 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CN107176933B (zh) * 2016-03-09 2020-10-09 中国科学院上海有机化学研究所 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂
CN109563081A (zh) 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
MY189100A (en) 2016-04-07 2022-01-25 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2017192811A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452029A4 (en) 2016-05-04 2019-10-30 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2017192815A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452451A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2017192844A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JOP20170131B1 (ar) * 2016-06-10 2021-08-17 Lilly Co Eli مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
ES3005961T3 (en) 2016-07-14 2025-03-17 Bristol Myers Squibb Company Antibodies against tim3 and uses thereof
JP2019521166A (ja) 2016-07-20 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
BR112019001980A2 (pt) * 2016-08-02 2019-05-07 Shandong Luye Pharmaceutical Co., Ltd. inibidor de ido1 e método de preparação e aplicação do mesmo
WO2018039430A1 (en) * 2016-08-24 2018-03-01 H. Lee Moffitt Cancer Center & Research Institute, Inc. Radiofluorinated carboximidamides as ido targeting pet tracer for cancer imaging
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3504185B1 (en) 2016-08-29 2021-11-24 Merck Sharp & Dohme Corp. Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
JP7358236B2 (ja) 2016-09-19 2023-10-10 ユニヴァーシティ オブ サウス フロリダ 腫瘍溶解性ウイルスを腫瘍に標的化する方法
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
WO2018072697A1 (zh) * 2016-10-17 2018-04-26 上海医药集团股份有限公司 含噁二唑环化合物、制备方法、中间体、组合物及应用
UY37466A (es) 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
US11168078B2 (en) 2016-11-28 2021-11-09 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
CN106866648B (zh) * 2017-01-03 2019-10-22 中国药科大学 邻苯二甲酰亚胺类吲哚胺-2,3-双加氧酶1抑制剂及其用途
CN106883224B (zh) * 2017-01-03 2019-10-22 中国药科大学 苯并含氮杂环类吲哚胺-2,3-双加氧酶1抑制剂及其用途
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2018136437A2 (en) 2017-01-17 2018-07-26 Tesaro, Inc. Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
CN106866571B (zh) * 2017-01-20 2018-06-29 中国药科大学 杂环脲类化合物及其药物组合物和应用
EP3585774B1 (en) * 2017-02-24 2021-11-10 Merck Sharp & Dohme Corp. Novel substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN106967004B (zh) * 2017-03-29 2019-09-17 中国药科大学 含脲基的ido1和ido2双重抑制剂、其制法及其医药用途
EP3600299B1 (en) * 2017-03-29 2022-11-30 Merck Sharp & Dohme LLC Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US20200031944A1 (en) 2017-03-31 2020-01-30 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
CN108689958B (zh) * 2017-04-05 2021-09-17 南京华威医药科技集团有限公司 一种含有肼基的吲哚胺2,3-双加氧化酶抑制剂
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI778050B (zh) 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 吲哚ahr抑制劑及其用途
JP6860237B2 (ja) * 2017-04-24 2021-04-21 南京薬捷安康生物科技有限公司 インドールアミン２，３−ジオキシゲナーゼ阻害剤及び適用
CN114920710B (zh) * 2017-04-27 2024-09-20 鲁南制药集团股份有限公司 亚氨脲衍生物
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109081818B (zh) * 2017-06-14 2022-04-22 南京华威医药科技集团有限公司 新型吲哚胺2,3-双加氧化酶抑制剂
CN109111438B (zh) * 2017-06-26 2021-11-02 正大天晴药业集团股份有限公司 用于ido抑制剂的脒类化合物
BR112019027259A2 (pt) 2017-06-30 2020-07-14 Bristol-Myers Squibb Company formas amorfas e cristalinas de inibidores da ido
WO2019011170A1 (zh) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
JP7186764B2 (ja) 2017-07-28 2022-12-09 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
MX2020001793A (es) 2017-08-17 2020-07-22 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
WO2019043170A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh POLY THERAPY BASED ON HSP70
KR102651946B1 (ko) 2017-08-31 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
JP7316263B2 (ja) 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
JP7034430B2 (ja) * 2017-09-01 2022-03-14 トランステラ サイエンシーズ （ナンジン）， インコーポレイテッド 重水素化インドールアミン２，３－ジオキシゲナーゼ阻害剤及びその使用
CN108863976B (zh) * 2017-09-11 2022-09-16 郑州泰基鸿诺医药股份有限公司 用作ido调节剂的化合物及其应用
WO2019055786A1 (en) 2017-09-14 2019-03-21 Lankenau Institute For Medical Research METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
WO2019074747A1 (en) * 2017-10-09 2019-04-18 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
US11111232B2 (en) 2017-10-09 2021-09-07 Merck Sharp & Dohme Corp. Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN111344297B (zh) 2017-10-10 2023-10-20 百时美施贵宝公司 作为抗癌剂的环二核苷酸
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
EP3697801B1 (en) 2017-10-16 2024-11-20 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN109678813A (zh) * 2017-10-18 2019-04-26 中国科学院上海有机化学研究所 吲哚胺-2,3-双加氧酶抑制剂盐及其制备方法
KR20200074214A (ko) 2017-11-01 2020-06-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
CN109748911B (zh) * 2017-11-06 2022-03-11 中国药科大学 一种含三氮唑的ido抑制剂、其制备方法及其医药用途
US11166959B2 (en) 2017-11-06 2021-11-09 Bristol-Myers Squibb Company Isofuranone compounds useful as HPK1 inhibitors
CN107987031A (zh) * 2017-12-01 2018-05-04 华东理工大学 一种靶向吲哚胺-2,3-双加氧酶1氮芥类抑制剂及其制备方法和应用
EP3724177A1 (en) 2017-12-12 2020-10-21 Phenex Discovery Verwaltungs-GmbH Oxalamides as modulators of indoleamine 2,3-dioxygenase
CN108003111A (zh) * 2017-12-14 2018-05-08 华东理工大学 一种hdac1和ido1双靶点抑制剂及其制备方法和应用
CN109942565B (zh) * 2017-12-20 2021-03-26 海创药业股份有限公司 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
CN110054622B (zh) * 2018-01-18 2021-02-23 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
CN108586378B (zh) 2018-01-22 2020-06-19 南京华威医药科技集团有限公司 吲哚胺2,3-双加氧化酶抑制剂及其制备方法和用途
CN110092750B (zh) 2018-01-29 2023-07-21 北京诺诚健华医药科技有限公司 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
ES2980374T3 (es) 2018-03-08 2024-10-01 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
MX2020009786A (es) 2018-03-21 2020-10-12 Five Prime Therapeutics Inc Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019185870A1 (en) 2018-03-29 2019-10-03 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
EP3773714A1 (en) 2018-04-12 2021-02-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
WO2019206800A1 (en) 2018-04-24 2019-10-31 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
US11866430B2 (en) 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
FI3814348T3 (fi) 2018-06-27 2023-09-22 Bristol Myers Squibb Co Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina
WO2020014132A2 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
TW202028235A (zh) 2018-07-11 2020-08-01 美商戊瑞治療有限公司 於酸性ｐｈ結合至含免疫球蛋白ｖ域之t細胞活化抑制子（ｖｉｓｔａ）之抗體
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
CN111689952A (zh) * 2019-03-14 2020-09-22 复旦大学 含硫代四元环结构的2,3-双加氧酶抑制剂及其制备方法和用途
CN111909107B (zh) * 2019-05-10 2023-02-03 药康众拓(江苏)医药科技有限公司 Ido/hdac双重抑制剂及其药物组合物和应用
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN111943906B (zh) * 2019-05-14 2023-12-15 中国医学科学院药物研究所 脒类衍生物、及其制法和药物组合物与用途
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
CN112062732B (zh) * 2019-06-10 2023-10-24 鲁南制药集团股份有限公司 一种ido抑制剂及其组合物、制备方法和用途
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
US20230192860A1 (en) 2019-09-19 2023-06-22 Bristol-Myers Squibb Company Antibodies Binding to Vista at Acidic pH
AR120481A1 (es) 2019-11-19 2022-02-16 Bristol Myers Squibb Co Compuestos útiles como inhibidores de la proteína helios
MX2022006308A (es) 2019-11-26 2022-06-22 Ikena Oncology Inc Derivados de carbazol polimorfos y usos de los mismos.
CN115151306A (zh) 2019-11-26 2022-10-04 百时美施贵宝公司 (r)-n-(4-氯苯基)-2-((1s，4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
IL294270A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted piperazine derivatives useful as t cell activators
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds useful as t cell activators
EP4081513B1 (en) 2019-12-23 2024-11-20 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
KR20220119458A (ko) 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 헤테로아릴 화합물
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN111138425A (zh) * 2020-01-06 2020-05-12 中国药科大学 三氮唑类衍生物及其制备方法与用途
AU2021206618A1 (en) 2020-01-06 2022-08-18 Hifibio, Inc. Anti-TNFR2 antibody and uses thereof
BR112022013494A2 (pt) 2020-01-07 2022-09-13 Hifibio Hk Ltd Anticorpo anti-galectina-9 e usos do mesmo
TW202140473A (zh) 2020-01-15 2021-11-01 美商纜圖藥品公司 Map4k1抑制劑
CN115485302A (zh) 2020-03-09 2022-12-16 百时美施贵宝公司 具有增强的激动剂活性的针对cd40的抗体
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
JP2023537131A (ja) 2020-08-10 2023-08-30 シャンハイ・シュンバイフイ・バイオテクノロジー・カンパニー・リミテッド Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022133083A1 (en) 2020-12-16 2022-06-23 Gossamer Bio Services, Inc. Compounds useful as t cell activators
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
EP4291558A1 (en) 2021-02-12 2023-12-20 F. Hoffmann-La Roche AG Bicyclic tetrahydroazepine derivatives for the treatment of cancer
CN113105366B (zh) * 2021-03-04 2022-05-24 中国药科大学 一类含苯基羟肟结构衍生物及其制法与用途
WO2022192145A1 (en) 2021-03-08 2022-09-15 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20230167067A (ko) 2021-04-05 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
CA3214244A1 (en) 2021-04-06 2022-10-13 Yan Chen Pyridinyl substituted oxoisoindoline compounds
CN117940438A (zh) 2021-07-14 2024-04-26 缆图药品公司 作为map4k1抑制剂的杂环化合物
CN117940406A (zh) 2021-07-15 2024-04-26 缆图药品公司 Map4k1抑制剂
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
CN118946556A (zh) 2022-02-01 2024-11-12 阿维纳斯运营公司 Dgk靶向化合物及其用途
CN119654312A (zh) 2022-08-08 2025-03-18 百时美施贵宝公司 用作t细胞活化剂的取代的四唑基化合物
CN119677740A (zh) 2022-08-09 2025-03-21 百时美施贵宝公司 用作t细胞活化剂的叔胺取代的双环化合物
TW202417001A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫吖呯衍生物
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
IL318163A (en) 2022-08-11 2025-03-01 Hoffmann La Roche TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2024233900A1 (en) 2023-05-10 2024-11-14 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
CN118908989B (zh) * 2024-10-10 2024-12-17 江苏长泰药业股份有限公司 一种用于预防肺结节恶性转化的丙酮酸盐衍生物纳米雾化剂及其制备方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236855A (en) 1964-01-17 1966-02-22 Merck & Co Inc Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en) 1964-02-19 1967-11-21 Sterling Drug Inc 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
DE1453353A1 (de) 1964-02-20 1970-01-15 Nottmeyer Maschf Heinrich Maschine zum Einpressen von Duebeln in eine vorgebohrte Platte oder dergleichen Werkstueck
US3286855A (en) 1965-06-01 1966-11-22 Standard Trailer Company Crane extension and resulting crane assembly
US3553228A (en) 1967-09-26 1971-01-05 Colgate Palmolive Co 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (de) 1970-08-17 1972-02-24 Fahlberg List Veb Neue herbizide Mittel
US3948928A (en) 1972-03-17 1976-04-06 Dainippon Pharmaceutical Co., Ltd. 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (me) 1973-09-05 1981-05-16
GB1501529A (en) 1975-09-11 1978-02-15 Philagro Sa Derivatives of amidoximes
FR2323683A1 (fr) 1975-09-11 1977-04-08 Philagro Sa Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4323681A (en) 1980-09-29 1982-04-06 American Home Products Corporation 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS58208275A (ja) * 1982-05-20 1983-12-03 Lion Corp ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
EP0132680B1 (de) * 1983-07-22 1987-01-28 Bayer Ag Substituierte Furazane
US4507485A (en) 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (ja) * 1984-03-13 1985-10-02 Toyo Jozo Co Ltd シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法
JPS6259283A (ja) 1985-09-10 1987-03-14 Kaken Pharmaceut Co Ltd セフアロスポリン化合物
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
JP2696342B2 (ja) * 1988-06-27 1998-01-14 日本曹達株式会社 アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
ES2051986T3 (es) 1988-07-05 1994-07-01 Akzo Nv Compuestos con actividad broncodilatadora.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH0420710A (ja) 1990-05-12 1992-01-24 Hitachi Home Tec Ltd ポットバーナの運転制御装置
JPH04297449A (ja) 1991-03-27 1992-10-21 Hokko Chem Ind Co Ltd Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤
JPH05186458A (ja) 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP2709677B2 (ja) * 1992-06-19 1998-02-04 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
FR2720396B1 (fr) 1994-05-27 1996-06-28 Adir Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5731315A (en) 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US5883102A (en) * 1995-10-17 1999-03-16 Astra Pharmaceuticals Limited Pharmaceutically active compounds
WO1997030047A1 (en) * 1996-02-17 1997-08-21 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en) 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
JPH11171702A (ja) 1997-09-24 1999-06-29 Takeda Chem Ind Ltd 害虫防除方法
WO1999029852A1 (en) * 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
ES2213929T3 (es) 1997-12-10 2004-09-01 Dainippon Ink And Chemicals, Inc. Derivados de oximas y productos quimicos para uso agricola que incluyen los mismos.
US6288088B1 (en) 1998-06-02 2001-09-11 Takeda Chemical Industries, Ltd. Oxadiazoline derivative and their use as insecticides
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
EP1075469B1 (en) 1999-03-03 2004-05-26 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
IL145772A0 (en) 1999-04-09 2002-07-25 Basf Ag Prodrugs of thrombin inhibitors
CN1164574C (zh) 1999-05-24 2004-09-01 三菱制药株式会社 苯氧基丙胺类化合物
JP2001158786A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 哺乳動物の外部寄生虫防除剤
JP2001158785A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 農薬組成物
ES2293980T3 (es) 2000-01-13 2008-04-01 Amgen Inc. Agentes antibacterianos.
JP2001233861A (ja) 2000-02-22 2001-08-28 Ube Ind Ltd ピラゾールオキシム化合物、その製法及び用途
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
RS99503A (en) 2001-06-18 2006-12-15 Applied Research Systems Ars Holding N.V. Pyrrolidine oxadiazole- and thiadiazole derivatives
EA007983B1 (ru) 2001-09-19 2007-02-27 Авентис Фарма С.А. Индолизины в качестве ингибиторов киназных белков
EP1438059A4 (en) * 2001-10-26 2008-01-23 Angiolab Inc COMPOSITION CONTAINING EXTRACT OF BROWN FROM INDIA PREPARED FOR ANTI-ANGIOGENIC ACTIVITY AND INHIBITOR OF MATRIX METALLOPROTEINASE
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CA2473026C (en) 2002-01-22 2011-05-03 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
MXPA04008680A (es) 2002-02-19 2004-12-06 Pharmacia Italia Spa Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales.
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
EP2177601A1 (en) 2002-04-12 2010-04-21 Medical College of Georgia Research Institute, Inc Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
BR0311419A (pt) 2002-05-28 2005-04-05 Dimensional Pharm Inc Amidinas de tiofeno suas composições e métodos de tratamento de doenças e condições mediadas por complemento
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
JP4020710B2 (ja) 2002-06-25 2007-12-12 株式会社ミツバ ドアミラーセットプレート
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7015321B2 (en) 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4921965B2 (ja) * 2003-03-27 2012-04-25 ランケナー インスティテュート フォー メディカル リサーチ 癌治療新規方式
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2005003175A2 (en) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
ATE536353T1 (de) 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
ES2396419T3 (es) 2004-09-08 2013-02-21 Mitsubishi Tanabe Pharma Corporation Compuestos de morfolina para el tratamiento de inflamaciones
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ME02461B (me) * 2005-05-10 2017-02-20 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
CN101252957A (zh) 2005-06-30 2008-08-27 人类起源公司 使用胎盘源胶原生物纤维的鼓膜修复
DE102005060466A1 (de) 2005-12-17 2007-06-28 Bayer Cropscience Ag Carboxamide
WO2007075598A2 (en) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (ja) 2006-05-12 2009-07-15 株式会社サクラクレパス 墨汁
WO2008036652A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2064207B1 (en) 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080182882A1 (en) 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7998995B2 (en) 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CA2709202C (en) 2007-12-19 2013-04-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CN104045654A (zh) 2010-10-25 2014-09-17 G1治疗公司 Cdk抑制剂
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CA2921203C (en) 2013-07-12 2021-07-27 Nippon Chemiphar Co., Ltd. Diazepinedione derivatives and compositions thereof useful as p2x4 receptor antagonist
EP3744715A1 (en) 2013-11-08 2020-12-02 Incyte Holdings Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
DK3981792T3 (da) 2015-07-30 2024-09-02 Macrogenics Inc PD-1-bindende molekyler og fremgangsmåder til anvendelse deraf
TN2018000069A1 (en) 2015-09-01 2019-07-08 First Wave Biopharma Methods and compositions for treating conditions associated with an abnormal inflammatory responses
CN108472245A (zh) 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
MX2022001133A (es) 2019-08-01 2022-04-25 Incyte Corp Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
WO2021222257A1 (en) 2020-04-27 2021-11-04 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating pseudomonas infection

Also Published As

Publication number Publication date
EP2559690A1 (en) 2013-02-20
HRP20160537T1 (hr) 2016-06-17
BRPI0608604B8 (pt) 2021-05-25
SG10201809390QA (en) 2018-11-29
IL232313A0 (en) 2014-06-30
HRP20130220T1 (hr) 2013-04-30
RS52711B (en) 2013-08-30
PT1879573E (pt) 2013-03-25
CN103130735B (zh) 2016-08-03
HK1117392A1 (en) 2009-01-16
BR122020016659B8 (pt) 2021-07-27
CY1117681T1 (el) 2017-05-17
EP1879573A1 (en) 2008-01-23
ZA200709698B (en) 2008-11-26
SG195607A1 (en) 2013-12-30
EP1879573B1 (en) 2012-12-19
PT2559690T (pt) 2016-07-07
AU2006244068B9 (en) 2012-10-25
AU2006244068A1 (en) 2006-11-16
KR20130109263A (ko) 2013-10-07
NO20075693L (no) 2008-02-07
US11192868B2 (en) 2021-12-07
CN103130735A (zh) 2013-06-05
NO340487B1 (no) 2017-05-02
CR9485A (es) 2008-02-20
EP2559690B1 (en) 2016-03-30
US20180030006A1 (en) 2018-02-01
JP4990270B2 (ja) 2012-08-01
US10208002B2 (en) 2019-02-19
US20110311479A1 (en) 2011-12-22
SI2559690T1 (sl) 2016-06-30
UA99897C2 (en) 2012-10-25
EA026785B1 (ru) 2017-05-31
US20060258719A1 (en) 2006-11-16
RS54876B1 (sr) 2016-10-31
IL186957A0 (en) 2008-02-09
SI1879573T1 (sl) 2013-04-30
TWI377060B (en) 2012-11-21
NO342140B1 (no) 2018-03-26
ES2401482T3 (es) 2013-04-22
EP3085697A1 (en) 2016-10-26
HK1182381A1 (zh) 2013-11-29
DK1879573T3 (da) 2013-02-25
AR054271A1 (es) 2007-06-13
KR101562549B1 (ko) 2015-10-23
ES2578404T3 (es) 2016-07-26
BRPI0608604A2 (pt) 2010-01-26
MX2007013977A (es) 2008-02-05
EP1879573A4 (en) 2009-07-08
US8372870B2 (en) 2013-02-12
EA200702455A1 (ru) 2008-04-28
BR122020016659B1 (pt) 2021-03-16
BRPI0608604B1 (pt) 2020-11-17
NO20170633A1 (no) 2008-02-07
TW200719892A (en) 2007-06-01
CA2606783C (en) 2014-03-25
AU2006244068B2 (en) 2012-06-14
JP5615308B2 (ja) 2014-10-29
DK2559690T3 (en) 2016-04-25
US8034953B2 (en) 2011-10-11
PL1879573T3 (pl) 2013-05-31
PL2559690T3 (pl) 2016-09-30
GEP20217221B (en) 2021-02-10
JP2012140450A (ja) 2012-07-26
IL232313A (en) 2016-05-31
NZ562919A (en) 2011-04-29
US20140377292A1 (en) 2014-12-25
CA2606783A1 (en) 2006-11-16
JP2008540548A (ja) 2008-11-20
KR101386494B1 (ko) 2014-04-24
IL186957A (en) 2014-04-30
US20130123246A1 (en) 2013-05-16
MY153424A (en) 2015-02-13
US20190210985A1 (en) 2019-07-11
US8846726B2 (en) 2014-09-30
SG161310A1 (en) 2010-05-27
HUE029214T2 (en) 2017-02-28
CN101212967A (zh) 2008-07-02
KR20080005954A (ko) 2008-01-15
CY1113989T1 (el) 2016-07-27
WO2006122150A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ME02461B (me) Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
JP2010504342A5 (me)
RU2461551C2 (ru) Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
RU2007141346A (ru) Диарилсульфонсульфонамиды и их применение
JP2009529557A5 (me)
RU2006101053A (ru) Производные бензамида или соль указанного производного
JP2015517981A5 (me)
JP2007519754A5 (me)
RU2008119412A (ru) N-фенил-фенилацетамидные ненуклеозидные ингибиторы обратной транскриптазы
JP2005521639A5 (me)
RU2007107189A (ru) Производные арилпиридина
ME02642B (me) Sulfonamid derivati i kao BCL- 2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti
ZA200502755B (en) 1,3-Diamino-2-hydroxypropane prodrug derivatives.
JP2009528354A5 (me)
RU2009116670A (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
RU2012129737A (ru) Замещенные бензамидные производные
JP2010520195A5 (me)
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
JP2010506918A5 (me)
KR101461294B1 (ko) Ｃｎｓ 장애 치료용 옥사졸린 유도체
NZ603724A (en) Piperidine derivatives and their use for the treatment of metabolic disorders
JP2011529037A5 (me)
RU2006101541A (ru) Производные пиперазина и способ их применения
MX2007012162A (es) Tratamiento de la enfermedad de de parkinson, la apnea obstructiva del sueno, la demencia con cuerpos de lewy, la demencia vascular con ligandos de receptor de h3 de histamina de alquilaminas que no contienen imidazol.
RU2013102401A (ru) Анеллированные производные пиридина